BioMarin Pharmaceutical Inc.
LSE: 0HNC.L0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- London Stock Exchange
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Alexander Hardy
- Employees
- 3,040
- Headquarters
- San Rafael, United States
- IPO year
- 2018
- Market cap
- $9.6B
- Website
- https://www.biomarin.com
Loading 0HNC…
Loading profile data…Frequently asked questions about 0HNC
What does BioMarin Pharmaceutical Inc. (0HNC.L) do?
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
Where does 0HNC.L trade?
BioMarin Pharmaceutical Inc. (0HNC.L) trades on the London Stock Exchange.
What sector is 0HNC.L in?
BioMarin Pharmaceutical Inc. (0HNC.L) operates in the Healthcare sector, specifically in the Medical - Pharmaceuticals industry.
Who is the CEO of BioMarin Pharmaceutical Inc.?
Alexander Hardy is the chief executive officer of BioMarin Pharmaceutical Inc. (0HNC.L).
Where is BioMarin Pharmaceutical Inc. headquartered?
BioMarin Pharmaceutical Inc. is headquartered in United States.
Does 0HNC.L pay a dividend?
BioMarin Pharmaceutical Inc. (0HNC.L) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 0HNC.L go public?
BioMarin Pharmaceutical Inc. (0HNC.L) completed its initial public offering in 2018.